[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Europe Cervical Cancer Diagnostic Market & Forecast, By Test Type (Pap smear and HPV DNA), Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands)

June 2018 | | ID: E92F55487CBEN
Renub Research

US$ 1,290.00

E-mail Delivery (PDF), Online Subscription, Hard Copy Mail Delivery, CD-ROM Mail Delivery, E-mail Delivery (Word)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Cervical cancer is one of the most serious public health issues in Europe. Despite introduction of vaccination in 21 European countries, still more than 23 Thousand women have died from cervical cancer across all over Europe. Cervical cancer incidence rate in Europe was 10.2 per 100,000 women population. Germany, France and United Kingdom are top three dominating countries in the Europe cervical cancer market in 2017. Cervical cancer generally occurs in women over 30 years. It is mostly caused by the Human papillomavirus (HPV) virus. Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences.

Increasing cervical cancer incidence rate is one of the key factors that drive the cervical cancer screening market. Rapidly increasing female population, growing prevalence of HPV infections and increasing awareness about cervical cancer screening programs is also expected to drive the cervical cancer screening market in the near future.

Renub Research report titled “Europe Cervical Cancer Diagnostic Market & Forecast, By Test Type (Pap smear and HPV DNA), Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands)” provides a complete analysis of Europe Cervical Cancer Screening Market. The covers European Countries Cervical Cancer Test Market Screened Population & Mortality.

By Test Types – Pap smear Screening Tests is gaining popularity in Europe

The report studies the market and population of the following cervical cancer screening tests: Pap smear Tests and HPV DNA Tests. Pap smear and HPV DNA tests are more popular with the developed countries such as Germany, United Kingdom and France.

By Country – Germany holds the largest share by population and market in Cervical Cancer Test

The report studies the market/screened population of Nine big European countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands) which provides a complete country-wise analysis of Europe Cervical Cancer Screening Market.

Cervical Cancer Screening Market
  • Pap Smear Tests Market
  • HPV DNA Tests Market
Cervical Cancer Test Population
  • Pap Smear Test Population
  • HPV DNA Test Population
Cervical Cancer Mortality Population of All 9 Countries

All the 9 Countries Studied in the Report are as Follows

1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Sweden
7. Switzerland
8. Norway
9. Netherlands
1. EXECUTIVE SUMMARY

2. EUROPE CERVICAL CANCER TEST (SCREENING) ANALYSIS

2.1 Europe Cervical Cancer Test Population
  2.1.1 Pap smear Test Population
  2.1.2 HPV DNA Test Population
2.2 Europe Cervical Cancer Test (Screening) Market
  2.2.1 Pap Smear Test Market
  2.2.2 HPV DNA Test Market

3. MARKET & POPULATION SHARE – BY COUNTRIES

3.1 Europe Cervical Cancer Test Population
  3.1.1 Pap smear Population
  3.1.2 HPV DNA Population
3.2 Market Share – By Countries
  3.2.1 Pap smear Market
  3.2.2 HPV DNA Market

4. UNITED KINGDOM – CERVICAL CANCER TEST ANALYSIS

4.1 Population – Cervical Cancer Test (Screening)
  4.1.1 Pap smear Test Population
  4.1.2 HPV DNA Test Population
4.2 United Kingdom Cervical Cancer Deaths
4.3 Market – Cervical Cancer Test (Screening)
  4.3.1 Pap smear Test Market
  4.3.2 HPV DNA Test Market

5. FRANCE – CERVICAL CANCER TEST ANALYSIS (2011 – 2024)

5.1 Population – Cervical Cancer Test (Screening)
  5.1.1 Pap smear Test Population
  5.1.2 HPV DNA Test Population
5.2 France Cervical Cancer Mortality
5.3 Market – Cervical Cancer Test (Screening)
  5.3.1 Pap Smear Test Market
  5.3.2 HPV DNA Test Market

6. GERMANY – CERVICAL CANCER TEST ANALYSIS (2011 – 2024)

6.1 Population – Cervical Cancer Test (Screening)
  6.1.1 Pap smear Test Population
  6.1.2 HPV DNA Test Population
6.2 Germany Cervical Cancer Mortality
6.3 Market – Cervical Cancer Test (Screening)
  6.3.1 Pap Smear Test Market
  6.3.2 HPV DNA Test Market

7. ITALY – CERVICAL CANCER TEST ANALYSIS (2011 – 2024)

7.1 Population – Cervical Cancer Test (Screening)
  7.1.1 Pap smear Test Population
  7.1.2 HPV DNA Test Population
7.2 Italy Cervical Cancer Mortality
7.3 Market – Cervical Cancer Test (Screening)
  7.3.1 Pap Smear Test Market
  7.3.2 HPV DNA Test Market

8. SPAIN – CERVICAL CANCER TEST ANALYSIS (2011 – 2024)

8.1 Population – Cervical Cancer Test (Screening)
  8.1.1 Pap smear Test Population
  8.1.2 HPV DNA Test Population
8.2 Spain Cervical Cancer Mortality
8.3 Market – Cervical Cancer Test (Screening)
  8.3.1 Pap Smear Test Market
  8.3.2 HPV DNA Test Market

9. SWEDEN – CERVICAL CANCER TEST ANALYSIS (2011 – 2024)

9.1 Population – Cervical Cancer Test (Screening)
  9.1.1 Pap smear Test Population
  9.1.2 HPV DNA Test Population
9.2 Sweden Cervical Cancer Mortality
9.3 Market – Cervical Cancer Test (Screening)
  9.3.1 Pap Smear Test Market
  9.3.2 HPV DNA Test Market

10. SWITZERLAND – CERVICAL CANCER TEST ANALYSIS (2011 – 2024)

10.1 Population – Cervical Cancer Test (Screening)
  10.1.1 Pap smear Test Population
  10.1.2 HPV DNA Test Population
10.2 Switzerland Cervical Cancer Mortality
10.3 Market – Cervical Cancer Test (Screening)
  10.3.1 Pap Smear Test Market
  10.3.2 HPV DNA Test Market

11. NORWAY – CERVICAL CANCER TEST ANALYSIS (2011 – 2024)

11.1 Population – Cervical Cancer Test (Screening)
  11.1.1 Pap smear Test Population
  11.1.2 HPV DNA Test Population
11.2 Norway Cervical Cancer Mortality
11.3 Market – Cervical Cancer Test (Screening)
  11.3.1 Pap Smear Test Market
  11.3.2 HPV DNA Test Market

12. NETHERLANDS – CERVICAL CANCER TEST ANALYSIS (2011 – 2024)

12.1 Population – Cervical Cancer Test (Screening)
  12.1.1 Pap smear Test Population
  12.1.2 HPV DNA Test Population
12.2 Netherlands Cervical Cancer Mortality
12.3 Market – Cervical Cancer Test (Screening)
  12.3.1 Pap Smear Test Market
  12.3.2 HPV DNA Test Market

13. GROWTH DRIVERS

13.1 Rising Incidence of Cervical Cancer in United Kingdom
13.2 Huge Prevalence of HPV Infected Patients in Europe

14. CHALLENGES

14.1 Introduction of HPV Vaccination Programs Globally
14.2 Hard to Prevent Cervical Cancer in Eastern Europe and Central Asia

LIST OF FIGURES:

Figure 2-1: Europe – Cervical Cancer Test Population (Million), 2011 – 2017
Figure 2-2: Europe – Forecast for Cervical Cancer Test Population (Million), 2018 – 2024
Figure 2-3: Europe – Cervical Cancer Pap smear Test Population (Million), 2011 – 2017
Figure 2-4: Europe – Forecast for Cervical Cancer Pap smear Test Population (Million), 2018 – 2024
Figure 2-5: Europe – Cervical Cancer HPV DNA Test Population (Million), 2011 – 2017
Figure 2-6: Europe – Forecast for Cervical Cancer HPV DNA Test Population (Million), 2018 – 2024
Figure 2-7: Europe – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 2-8: Europe – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 2-9: Europe – Cervical Cancer Pap smear Test Market (Million US$), 2011 – 2017
Figure 2-10: Europe – Forecast for Cervical Cancer Pap smear Test Market (Million US$), 2018 – 2024
Figure 2-11: Europe – Cervical Cancer HPV DNA Test Market (Million US$), 2011 – 2017
Figure 2-12: Europe – Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2018 – 2024
Figure 3-1: Europe – Cervical Cancer Test Population Share (%), 2011 – 2017
Figure 3-2: Europe – Forecast for Cervical Cancer Test Population Share (%), 2018 – 2024
Figure 3-3: Europe – Cervical Cancer Pap smear Test Population Share (%), 2011 – 2017
Figure 3-4: Europe – Forecast for Cervical Cancer Pap smear Test Population Share (%), 2018 – 2024
Figure 3-5: Europe – Cervical Cancer HPV DNA Test Population Share (%), 2011 – 2017
Figure 3-6: Europe – Forecast for Cervical Cancer HPV DNA Test Population Share (%), 2018 – 2024
Figure 3-7: Europe – Cervical Cancer Test Market Share (%), 2011 – 2017
Figure 3-8: Europe – Forecast for Cervical Cancer Test Market Share (%), 2018 – 2024
Figure 3-9: Europe – Cervical Cancer Pap smear Test Market Share (%), 2011 – 2017
Figure 3-10: Europe – Forecast for Cervical Cancer Pap smear Test Market Share (%), 2018 – 2024
Figure 3-11: Europe – Cervical Cancer HPV DNA Test Market Share (%), 2011 – 2017
Figure 3-12: Europe – Forecast for Cervical Cancer HPV DNA Test Market Share (%), 2018 – 2024
Figure 4-1: United Kingdom – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 4-2: United Kingdom – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 4-3: United Kingdom – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 4-4: United Kingdom – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 4-5: United Kingdom – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 4-6: United Kingdom – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 4-7: United Kingdom – Cervical Cancer Deaths (Number), 2011 – 2017
Figure 4-8: United Kingdom – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 4-9: United Kingdom – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 4-10: United Kingdom – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 4-11: United Kingdom – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 4-12: United Kingdom – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 4-13: United Kingdom – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 5-1: France – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 5-2: France – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 5-3: France – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 5-4: France – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 5-5: France – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 5-6: France – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 5-7: France – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 5-8: France – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 5-9: France – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 5-10: France – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 5-11: France – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 5-12: France – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 5-13: France – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 6-1: Germany – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 6-2: Germany – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 6-3: Germany – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 6-4: Germany – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 6-5: Germany – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 6-6: Germany – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 6-7: Germany – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 6-8: Germany – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 6-9: Germany – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 6-10: Germany – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 6-11: Germany – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 6-12: Germany – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 6-13: Germany – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 7-1: Italy – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 7-2: Italy – Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 7-3: Italy – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 7-4: Italy – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 7-5: Italy – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 7-6: Italy – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 7-7: Italy – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 7-8: Italy – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 7-9: Italy – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 7-10: Italy – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 7-11: Italy – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 7-12: Italy – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 7-13: Italy – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 8-1: Spain – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 8-2: Spain – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 8-3: Spain – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 8-4: Spain – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 8-5: Spain – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 8-6: Spain – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 –2024
Figure 8-7: Spain – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 8-8: Spain – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 8-9: Spain – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 8-10: Spain – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 8-11: Spain – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 8-12: Spain – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 8-13: Spain – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 9-1: Sweden – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 9-2: Sweden – Forecast for Cervical Cancer Pap smear Test Population (Thousand), 2018 – 2024
Figure 9-3: Sweden – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 9-4: Sweden – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 9-5: Sweden – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 9-6: Sweden – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 9-7: Sweden – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 9-8: Sweden – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 9-9: Sweden – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 9-10: Sweden – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 9-11: Sweden – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 9-12: Sweden – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 9-13: Sweden – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 10-1: Switzerland – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 10-2: Switzerland – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 10-3: Switzerland – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 10-4: Switzerland – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 10-5: Switzerland – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 10-6: Switzerland – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 10-7: Switzerland – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 10-8: Switzerland – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 10-9: Switzerland – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 10-10: Switzerland – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 10-11: Switzerland – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 10-12: Switzerland – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 10-13: Switzerland – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 11-1: Norway – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 11-2: Norway – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 11-3: Norway – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 11-4: Norway – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 11-5: Norway – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 11-6: Norway – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 11-7: Norway – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 11-8: Norway – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 11-9: Norway – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 11-10: Norway – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 11-11: Norway – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 11-12: Norway – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 11-13: Norway – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024
Figure 12-1: Netherlands – Cervical Cancer Test Population (Thousand), 2011 – 2017
Figure 12-2: Netherlands – Forecast for Cervical Cancer Test Population (Thousand), 2018 – 2024
Figure 12-3: Netherlands – Cervical Cancer Pap Smear Test Population (Thousand), 2011 – 2017
Figure 12-4: Netherlands – Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2018 – 2024
Figure 12-5: Netherlands – Cervical Cancer HPV DNA Test Population (Thousand), 2011 – 2017
Figure 12-6: Netherlands – Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2018 – 2024
Figure 12-7: Netherlands – Cervical Cancer Mortality (Number), 2011 – 2017
Figure 12-8: Netherlands – Cervical Cancer Test Market (Million US$), 2011 – 2017
Figure 12-9: Netherlands – Forecast for Cervical Cancer Test Market (Million US$), 2018 – 2024
Figure 12-10: Netherlands – Pap Smear Test Market (Million US$), 2011 – 2017
Figure 12-11: Netherlands – Forecast for Pap Smear Test Market (Million US$), 2018 – 2024
Figure 12-12: Netherlands – HPV DNA Test Market (Million US$), 2011 – 2017
Figure 12-13: Netherlands – Forecast for HPV DNA Test Market (Million US$), 2018 – 2024

LIST OF TABLES:

Table 13-1: United Kingdom – Number of Incidence Observed and Projected and their respective Age Standardized Rate, 2010 - 2025
Table 13-2: Europe – Prevalence of HPV among women with normal cervical cytology in Europe by country and study, 2016


More Publications